Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織,我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
Tuesday, 28 March 2023, 19:00 HKT/SGT

來源 Envision Pharma Group
Envision Pharma Group Appoints Richard Gorman as President, Strategic Consulting

PHILADELPHIA, PA, 2023年3月28日 - (亞太商訊)  - Envision Pharma Group (Envision) has appointed Richard "Rich" Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.

Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.

Rich will be responsible for leading the Strategic Consulting business across Envision's commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients' strategies.

Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.

Rich shares, "I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients."

Meg Heim, Chief Executive Officer of Envision Pharma Group, states, "We are so excited to have Rich join our team as we continue to accelerate Envision's business expansion, mission, and commitment to our clients' needs. Rich's proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise."

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at

Contact Information
Colleen Carter
1 (508) 505 8856

SOURCE: Envision Pharma Group

話題 Press release summary

部門 制药及生物技术, 健康与医药, 人力资源
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network

Envision Pharma Group
May 10, 2023, 14:00 HKT/SGT
Envision Pharma Group Announces Appointment of Dr. Deepti Sodhi Jaggi to Board of Directors
May 4, 2023, 19:00 HKT/SGT
Envision Pharma Group Appoints Healthcare Industry Expert and Experienced Leader Dr. Jennifer Costello, PharmD, BCPS, CMPP, as Chief Medical Officer
May 2, 2023, 19:00 HKT/SGT
Envision Pharma Group Appoints Mike Glover to Senior Vice President, Payer and HTA Solutions to Drive Acceleration and Expansion in Value & Access and Data Analytics
更多新闻 >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
美國: +1 214 890 4418 | 北京: +86 400 879 3881 | 香港: +852 8192 4922 | 新加坡: +65 6549 7068 | 東京: +81 3 6859 8575